Abbott Labs

ABT-N

NYSE:ABT

94.92
2.82 (3.06%)
Abbott Laboratories is a multinational health care company with headquarters in Lake Bluff, Illinois.
More at Wikipedia

Analysis and Opinions about ABT-N

Signal
Opinion
Expert
BUY WEAKNESS
BUY WEAKNESS
November 19, 2010
Good entry point at the support level of around $46. If it corrects and holds at $46, that is pretty powerful. Crummy relative strength, which is a pretty good sign. Do a partial Buy at $46 and another at around $43 and a final one at $41.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
November 19, 2010
Good entry point at the support level of around $46. If it corrects and holds at $46, that is pretty powerful. Crummy relative strength, which is a pretty good sign. Do a partial Buy at $46 and another at around $43 and a final one at $41.
TOP PICK
TOP PICK
July 26, 2010
Diversified healthcare in the US. Have a branded pharmaceutical business providing drugs for arthritis, cholesterol and prostate cancer. Also had a nutritional business providing babies formula and adults’ nutrition. Also have stents, which is doing quite well globally. Trading at about 10.5X forward earnings. About 3.6% yield and have increased dividends on a regular basis.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
July 26, 2010
Diversified healthcare in the US. Have a branded pharmaceutical business providing drugs for arthritis, cholesterol and prostate cancer. Also had a nutritional business providing babies formula and adults’ nutrition. Also have stents, which is doing quite well globally. Trading at about 10.5X forward earnings. About 3.6% yield and have increased dividends on a regular basis.
DON'T BUY
DON'T BUY
May 27, 2010
The model price is $48.13, a 2% upside only. Fully priced.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
May 27, 2010
The model price is $48.13, a 2% upside only. Fully priced.
BUY
BUY
May 12, 2010
Have a little less than 50% of their business in pharmaceuticals. Their big drug is Humera for rheumatoid arthritis and doesn't come off patent until 2016. Also have about 20%-25% revenues from their nutritional business.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
May 12, 2010
Have a little less than 50% of their business in pharmaceuticals. Their big drug is Humera for rheumatoid arthritis and doesn't come off patent until 2016. Also have about 20%-25% revenues from their nutritional business.
TOP PICK
TOP PICK
April 26, 2010
Pharma company. Nutritional division. Adult’s nutrition. Likes the diversification. Consistently increases dividend, about 3-1/2% at present. Recently beat numbers. Pulled earning back by 7%, but it is manageable.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
April 26, 2010
Pharma company. Nutritional division. Adult’s nutrition. Likes the diversification. Consistently increases dividend, about 3-1/2% at present. Recently beat numbers. Pulled earning back by 7%, but it is manageable.
BUY
BUY
April 14, 2010
Great company with a great pipeline. Humira, a rheumatoid arthritis drug, is their major product is on patent until 2016. Have never had a down year in stock price since 1992.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
April 14, 2010
Great company with a great pipeline. Humira, a rheumatoid arthritis drug, is their major product is on patent until 2016. Have never had a down year in stock price since 1992.
COMMENT
COMMENT
January 14, 2010
Not hot on pharmaceuticals because of generic manufacturing and litigation risks. This one is a pretty good choice in pharmaceuticals with a pretty good product line up going forward. A lower risk way to play pharmaceuticals is through Johnson & Johnson (JNJ-N) that has both pharmaceuticals and branded consumer products.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
January 14, 2010
Not hot on pharmaceuticals because of generic manufacturing and litigation risks. This one is a pretty good choice in pharmaceuticals with a pretty good product line up going forward. A lower risk way to play pharmaceuticals is through Johnson & Johnson (JNJ-N) that has both pharmaceuticals and branded consumer products.
TOP PICK
TOP PICK
January 13, 2010
Trading at about 13X earnings. Expects revenues to grow at 8%-10% and earnings to grow 12%-14%. 2.9% dividend. 7.5% free cash flow.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
January 13, 2010
Trading at about 13X earnings. Expects revenues to grow at 8%-10% and earnings to grow 12%-14%. 2.9% dividend. 7.5% free cash flow.
BUY
BUY
July 8, 2009
Medical company, pharma and diagnostics. Good solid holding. Pays a good dividend. Good core holding for a portfolio.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
July 8, 2009
Medical company, pharma and diagnostics. Good solid holding. Pays a good dividend. Good core holding for a portfolio.
TOP PICK
TOP PICK
November 21, 2008
Diagnostic equipment stents and some new blockbuster drugs. Drug industry and healthcare services might come under some pressure with the new administration, which is the risk they may face.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
November 21, 2008
Diagnostic equipment stents and some new blockbuster drugs. Drug industry and healthcare services might come under some pressure with the new administration, which is the risk they may face.
BUY
BUY
August 29, 2007
In the healthcare area this is an attractive name. Have medical devices, nutrition products and pharmaceuticals. Had troubles a few years ago but has gotten its act together.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
August 29, 2007
In the healthcare area this is an attractive name. Have medical devices, nutrition products and pharmaceuticals. Had troubles a few years ago but has gotten its act together.
DON'T BUY
DON'T BUY
August 25, 2005
Pharmaceuticals is a group that has underperformed for about 3 years. This one, in relation to the rest of the group, has peformed better althoough all of them are retracing over the last couple of months. Prefers the bioceutical companies.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
August 25, 2005
Pharmaceuticals is a group that has underperformed for about 3 years. This one, in relation to the rest of the group, has peformed better althoough all of them are retracing over the last couple of months. Prefers the bioceutical companies.
TOP PICK
TOP PICK
May 21, 2004
Has paid a dividend for 80 years. Trades at a discount to the market multiple but has new drug pipeline coming on. As simple, safe story.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
May 21, 2004
Has paid a dividend for 80 years. Trades at a discount to the market multiple but has new drug pipeline coming on. As simple, safe story.
BUY
BUY
April 30, 2004
Attractive. Continuing turnaround in their diagnostic business as well as a better pipeline than some of the other chief pharmaceuticals.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
April 30, 2004
Attractive. Continuing turnaround in their diagnostic business as well as a better pipeline than some of the other chief pharmaceuticals.
BUY
BUY
September 3, 2003
Spinning off their hospital products division. A good strategy as there is not much growth. Not too expensive.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
September 3, 2003
Spinning off their hospital products division. A good strategy as there is not much growth. Not too expensive.
Showing 106 to 120 of 122 entries